| Private Placement / Financing Transactions
Cerevance: The company raised $163 million of Series B venture funding in a deal led by Agent Capital, Bioluminescence Ventures and Double Point Ventures on April 25, 2024. GV, Takeda Ventures, UPMC Enterprises, Foresite Capital, Casdin Capital, Dolby Family Ventures, Gates Frontier, MQB Partners, LifeRock Ventures, Lightstone Ventures, SV Health Investors and William Gates also participated in the round. The company is a developer of novel therapeutics intended to advance new medicines for central nervous system diseases.
Endeavor BioMedicines: The company raised $132.5 million of Series C venture funding in a deal led by Matrix Capital Management on April 24, 2024, putting the company’s pre-money valuation at $530 million. Silver Arch Bio, Ally Bridge Group, The Invus Group, Velosity Capital, Omega Funds, Longitude Capital, SymBiosis Capital Management, Eckuity, Abrdn, Woodline Partners, Avidity Partners, Perceptive Advisors, Piper Sandler, T. Rowe Price and Fidelity Management & Research also participated in the round. The company is an operator of a clinical-stage business committed to developing new treatments targeting the underlying causes of pulmonary fibrosis.
SynOx Therapeutics: The company raised $75 million of Series B venture funding in a deal led by HealthCap, Forbion and Bioqube Ventures on April 22, 2024. The company is a developer of best-in-class humanized monoclonal antibodies intended to significantly improve the lives of people living with Tenosynovial giant cell tumors (TGCT) and other CSF-1 and macrophage-mediated diseases.
Rubedo: The company raised $40 million in Series A venture funding in a deal led by Khosla Ventures and Ahren Innovation Capital on April 22, 2024, putting the company’s pre-money valuation at $50 million. Hevolution Foundation, Cerigo Investments, Oscar & Paul, Shanda Group, R42 Group, Modi Ventures, LongeVC, Refactor Capital, Italian Angels for Growth and other undisclosed investors also participated in the round. The company is an operator of a biopharmaceutical company intended to commercialize novel therapeutics that target and eliminate senescent cells.
Variantyx: The company raised $36 million of venture funding from Bosch Ventures, Peregrine Ventures and Pitango Venture Capital on April 26, 2024. New Era Capital Partners also participated in the round. The company is a developer of a whole genome analytical technology designed to diagnose and generate clinical reports for rare inherited disorders.
AccessHope: The company raised $33 million of Series B venture funding from City of Hope on April 22, 2024. The company is a provider of cancer breakthrough services, cancer centers and employer oncology programs.
AtaCor Medical: The company raised $28 million in Series C venture funding in a deal led by Arboretum Ventures on April 24, 2024, putting the company’s pre-money valuation at $52 million. Hatteras Venture Partners, Catalyst Health Ventures, BayMed Venture Partners, and Long View Equity Partners also participated in the round. The company is a developer of a medical device designed for cardiac pacing and rhythm management.
Qlaris Bio: The company raised $24 million of Series B venture funding from undisclosed investors on April 22, 2024, putting the company’s pre-money valuation at $44 million. The company is a developer of novel therapies designed to treat serious and debilitating ophthalmic diseases.
Immagene: The company raised EUR 20 million of Series A venture funding in a deal led by V-Bio Ventures on April 24, 2024. Johnson & Johnson Innovation, Qbic Fund, Flanders Future Techfund, Swanbridge Capital, Oncode Oncology Bridge Fund, Brabantse Ontwikkelings Maatschappij and Curie Capital also participated in the round. The company is an operator of a biotech platform intended to develop precision immuno-oncology treatments.
CN-Bio: The company raised $21 million of Series B venture funding from CN Innovations, Bayland Capital and other undisclosed investors on April 23, 2024. The company is an operator of a leading organ-on-a-chip company intended to develop micro-physiological systems and solutions for the study of human biology, disease and drug response.
Siren Biotechnology: The company raised $19.6 million in Series A venture funding from Founders Fund, Lux Capital and Innovation Endeavors on April 22, 2024, putting the company’s pre-money valuation at $55 million. ARTIS Ventures, Civilization Ventures, Savantus Ventures, Carnrite Ventures, NZVC and Endless Frontier Labs also participated in the round. The company is an operator of a biotech business intended to provide a gene therapy platform for a variety of cancer treatments.
Exo Biologics: The company raised EUR 16 million of Series A venture funding from Family Office, Noshaq and Founders on April 24, 2024. Walloon Region also participated in the round. The company is a developer of novel therapeutic candidates based on exosomes designed to assist in treating dysplasia and Crohn’s disease.
Macro Biologics: The company raised $16.7 million of venture funding from undisclosed investors on April 24, 2024. The company is an operator of a biotechnology business intended to prevent and treat life-threatening infections.
LightOx: The company raised $10 million of Series A venture funding from undisclosed investors on April 23, 2024. The company is a developer of cancer therapeutics and technology designed to improve patients’ function and long-term outcomes with oral cancer.
Gordian Biotechnology: The company raised $8.5 million of venture funding from Athos Service, GigaFund and Founders Fund on April 26, 2024. Arctic Ventures also participated in the round. The company is a developer of a gene therapy discovery platform designed to improve therapeutic research for complex diseases related to aging.
Owlstone Medical: The company raised $5 million of venture funding from the Bill & Melinda Gates Foundation on April 25, 2024. The company is a developer of a breathalyzer designed to focus on non-invasive diagnostics for the early detection of disease, and precision medicine.
Pixacare: The company raised EUR 3 million of venture funding through a combination of debt and equity in a deal led by Elaia Partners on April 25, 2024. 50 Partners and Bpifrance also participated in the round. The company is a developer of a medical imaging system designed to transform the smartphone camera into a secure documentation tool.
Soundable: The company raised an undisclosed amount of Series A venture funding from Delight Room on April 23, 2024. The company is a developer of artificial intelligence sound technology designed to understand and manage health and diseases through digital audible biomarkers.
|
